lukair montelukast (as sodium) 5 mg chewable tablet blister pack
organon pharma pty ltd - montelukast sodium, quantity: 5.2 mg (equivalent: montelukast, qty 5 mg) - tablet, chewable - excipient ingredients: mannitol; hyprolose; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; iron oxide red; aspartame; flavour - prophylaxis and treatment of chronic asthma in adults and children two years of age and older. symptomatic treatment of seasonal allergic rhinitis
apo-montelukast
apotex nz ltd - montelukast sodium 5.2mg equivalent to 5 mg montelukast - chewable tablet - 5 mg - active: montelukast sodium 5.2mg equivalent to 5 mg montelukast excipient: aspartame cherry flavour 501027 ap0551 croscarmellose sodium iron oxide red magnesium stearate mannitol microcrystalline cellulose - apo-montelukast is indicated in adult and paediatric patients 2 years of age and older for the prophylaxis and chronic treatment of asthma, including the prevention of day- and night-time symptoms and the prevention of exercise-induced bronchospasm.
montelukast sodium- montelukast sodium tablet, chewable
camber pharmaceuticals, inc. - montelukast (unii: mhm278sd3e) (montelukast - unii:mhm278sd3e) - montelukast 4 mg - montelukast sodium chewable tablets are indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 2 years of age and older. montelukast sodium chewable tablets are indicated for prevention of exercise-induced bronchoconstriction (eib) in patients 6 years of age and older. sodium chewable tablets are indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 2 of age and older. because the benefits of montelukast sodium chewable tablets may not outweigh the risk of neuropsychiatric symptoms in patients with allergic rhinitis , use for patients who have an inadequate response or intolerance to alternative therapies. montelukast sodium chewable tablets are indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 2 years of age and older. because the ben
lukafast montelukast (as sodium) 5mg chewable tablet bottle
strides pharma science pty ltd - montelukast sodium, quantity: 5.19 mg - tablet, chewable - excipient ingredients: mannitol; microcrystalline cellulose; hyprolose; croscarmellose sodium; iron oxide red; aspartame; magnesium stearate; flavour - prophylaxis and treatment of chronic asthma in adults and children 2 years of age and older. symptomatic treatment of seasonal allergic rhinitis.
asthakast 5 montelukast (as sodium) 5 mg chewable tablet blister pack
torrent australasia pty ltd - montelukast sodium, quantity: 5.2 mg (equivalent: montelukast, qty 5 mg) - tablet, chewable - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; magnesium stearate; mannitol; aspartame; iron oxide red; flavour - prophylaxis and treatment of chronic asthma in adults and children 2 years of age and older. symptomatic treatment of seasonal allergic rhinitis.
montas-5mg chewable tab as sodium 5 mg
مستودع أدوية النور - noor drug store - montelukast as sodium 5 mg - as sodium 5 mg
montelukast sodium granule montelukast sodium tablet, chewable montelukast sodium- montelukast tablet, chewable montelukast s
ajanta pharma usa inc. - montelukast sodium (unii: u1o3j18sfl) (montelukast - unii:mhm278sd3e) - montelukast 4 mg - montelukast sodium tablets, chewable tablets and oral granules are indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months of age and older. montelukast sodium tablets and chewable tablets are indicated for prevention of exercise-induced bronchoconstriction (eib) in patients 6 years of age and older. montelukast sodium tablets, chewable tablets and oral granules are indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and older. because the benefits of montelukast sodium tablets, chewable tablets and oral granules may not outweigh the risk of neuropsychiatric symptoms in patients with allergic rhinitis [see warnings and precautions (5.1)] , reserve use for patients who have an inadequate response or intolerance to alternative therapies. montelukast sodium tablets, chewable tablets and oral granules are not indicated for the treatment of an acute asth
montelukast sodium tablet, chewable montelukast sodium tablet montelukast sodium granule
torrent pharmaceuticals limited - montelukast sodium (unii: u1o3j18sfl) (montelukast - unii:mhm278sd3e) - montelukast 4 mg - montelukast sodium is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months of age and older. montelukast sodium is indicated for prevention of exercise-induced bronchoconstriction (eib) in patients 6 years of age and older. montelukast sodium is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and older. because the benefits of montelukast sodium may not outweigh the risk of neuropsychiatric symptoms in patients with allergic rhinitis [see warnings and precautions (5.1)] , reserve use for patients who have an inadequate response or intolerance to alternative therapies. montelukast sodium is not indicated for the treatment of an acute asthma attack. montelukast sodium is contraindicated in patients with hypersensitivity to any of its components. risk summary available data from published prospective and retrospective cohort studies over
montelukast sodium tablet montelukast sodium tablet, chewable
hikma pharmaceuticals usa inc. - montelukast sodium (unii: u1o3j18sfl) (montelukast - unii:mhm278sd3e) - montelukast 10 mg - montelukast sodium tablets and montelukast sodium chewable tablets are indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 2 years of age and older. montelukast sodium tablets and montelukast sodium chewable tablets are indicated for prevention of exercise-induced bronchoconstriction (eib) in patients 6 years of age and older. montelukast sodium tablets and montelukast sodium chewable tablets are indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 2 years of age and older. because the benefits of montelukast sodium may not outweigh the risk of neuropsychiatric symptoms in patients with allergic rhinitis [see warnings and precautions ( 5.1)] , reserve use for patients who have an inadequate response or intolerance to alternative therapies. montelukast sodium tablets and montelukast sodium chewable tablets are not indicated for the treatment of an acute asthma attack. ris
singulair montelukast (as sodium) 5 mg chewable tablet blister
organon pharma pty ltd - montelukast sodium, quantity: 5.2 mg (equivalent: montelukast, qty 5 mg) - tablet, chewable - excipient ingredients: hyprolose; aspartame; mannitol; microcrystalline cellulose; croscarmellose sodium; iron oxide red; magnesium stearate; flavour - prophylaxis and treatment of chronic asthma in adults and children over two years. symptomatic treatment of seasonal allergic rhinitis